Early timing of low-dose dexamethasone decreases inflammation in a murine model of eosinophilic airway disease

Acta Oto-Laryngologica

Volumn 129, Issue 2, 2009, Pages 182-189

  Georén, Susanna Kumlien ^a,b   Tcacencu, Ion ^a   Wikström, Ann Charlotte ^a   Stierna, Pontus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Airway; Allergy; Eosinophil; Glucocorticoids; Inflammation; Low dose; Ovalbumin

Indexed keywords

DEXAMETHASONE; OVALBUMIN;

ALLERGIC RHINITIS; ALLERGY TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW; CONTROLLED STUDY; EOSINOPHILIA; INFLAMMATORY CELL; LOW DRUG DOSE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; PROVOCATION TEST; REPEATED DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MARROW; BRONCHOALVEOLAR LAVAGE FLUID; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILIA; EOSINOPHILS; INJECTIONS, INTRAPERITONEAL; LEUKOCYTE COUNT; LEUKOTRIENE B4; LUNG; MALE; MICE; MICE, INBRED BALB C; NASAL MUCOSA; OVALBUMIN; PREMEDICATION; PULMONARY EOSINOPHILIA; RESPIRATORY HYPERSENSITIVITY;

EID: 60549092141     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480802126561     Document Type: Article

References (20)

1. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-72.
2. Trifilieff A, El-Hashim A, Bertrand C. Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. Am J Physiol Lung Cell Mol Physiol 2000;6:1120-8.
3. De Bie JJ, Hessel EM, Van Ark I, Van Esch B, Hofman G, Nijkamp FP, et al. Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse. Br J Pharmacol 1996;119:1484-90.
4. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
5. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440-6.
6. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987;316:1506-10.
7. Ohkawara Y, Lei X-F, Stämpfli MR, Marshall JS, Xing Z, Jordana M. Cytokine and eosinophil responses in lung, peripheral blood and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 1997;16:1510-20.
8. Buske-Kirschbaum A, Jobst S, Hellhammer DH. Altered reactivity of the hypothalamus-pituitary-adrenal axis in patients with atopic dermatitis: pathologic factor or symptom? Ann N Y Acad Sci 1998;840:747-54.
9. Chung HT, Samlowski WE, Daynes RA. Modification of the murine immune system by glucocorticosteroids: alterations of the tissue localization properties of circulating lymphocytes. Cell Immunol 1986;101:571-85.
10. Korsgren M, Erjefalt JS, Korsgren O, Sundler F, Persson CG. Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J Exp Med 1997;185:885-92.
11. Peebles RS Jr, Togias A, Bickel CA, Diemer FB, Hubbard WC, Schleimer RP. Endogenous glucocorticoids and antigen-induced acute and late phase pulmonary responses. Clin Exp Allergy 2000;30:1257-65.
12. Okret S, Dong Y, Bronnegard M, Gustafsson JA. Regulation of glucocorticoid receptor expression. Biochimie 1991;73:51-9.
13. McCusker C, Chicoine M, Hamid Q, Mazer B. Site-specific sensitization in a murine model of allergic rhinitis: role of the upper airway in lower airways disease. J Allergy Clin Immunol 2002;110:891-8.
14. Hellings PW, Ceuppens JL. Mouse models of global airway allergy: what have we learned and what should we do next? Allergy 2004;59:914-19.
15. Reed CJ, Robinson DA, Lock EA. Antioxidant status of the rat nasal cavity. Free Radic Biol Med 2003;34:607-15.
16. Georen S, Ahnblad P, Stjarne P, Wikstrom AC, Stierna P. Significance of endogenous glucocorticoid sensitivity for airway eosinophilia in a murine model of allergy. Acta Otolaryngol 2005;125:378-85.
17. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Pharmacol Res 1999;40:15-29.
18. Hellings PW, Hessel EM, van den Oord JJ, Kasran A, van Hecke P, Ceuppens JL. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyperreactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 2001;31:782-90.
19. Pasquale CP, Lima MC, Bandeira-Melo C, Cordeiro RS, Silva PM, Martins MA. Systemic and local dexamethasone treatments prevent allergic eosinophilia in rats via distinct mechanisms. Eur J Pharmacol 1999;368:67-74.
20. Wood LJ, Sehmi R, Gauvreau GM, Watson RM, Foley R, Denburg JA, et al. An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. Am J Respir Crit Care Med 1999;159(5 Pt 1):1457-63.